TITLE

Current Application of Continuous Glucose Monitoring in the Treatment of Diabetes

AUTHOR(S)
HERMANIDES, JEROEN; PHILLIP, MOSHE; DE VRIES, J. HANS
PUB. DATE
May 2011
SOURCE
Diabetes Care;May2011 Supplement 2, Vol. 34, pS197
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the pros and cons of continuous glucose monitoring (CGM) in the treatment of diabetes. In developing diabetes technology, a main goal is to create an artificial pancreas or closed loop system. In the 1980s, the continuous subcutaneous insulin infusion (CSII) pump became commercially available in the U.S. market. One factor to consider when evaluating the advantages of using CGM is its glycosylated hemoglobin (HbA1c)-lowering potency. On the cons section, the value of CGM use is limited only to the most motivated patients.
ACCESSION #
61968011

 

Related Articles

  • The Future of Continuous Glucose Monitoring: Closed Loop. Hovorka, Roman // Current Diabetes Reviews;2008, Vol. 4 Issue 3, p269 

    Improvements in accuracy of real-time continuous glucose monitoring facilitate the development of closed-loop systems consisting of a continuous glucose monitor, a control algorithm, and an insulin pump. Closed-loop systems can be divided according to the way meal delivery is handled as "fully...

  • Fully Integrated Artificial Pancreas in Type 1 Diabetes. Breton, Marc; Farret, Anne; Bruttomesso, Daniela; Anderson, Stacey; Magni, Lalo; Patek, Stephen; Man, Chiara Dalla; Place, Jerome; Demartini, Susan; Favero, Simone Del; Toffanin, Chiara; Hughes-Karvetski, Colleen; Dassau, Eyal; Zisser, Howard; Doyle III, Francis J.; De Nicolao, Giuseppe; Avogaro, Angelo; Cobelli, Claudio; Renard, Eric; Kovatchev, Boris // Diabetes;Sep2012, Vol. 61 Issue 9, p2230 

    Integrated closed-loop control (CLC), combining continuous glucose monitoring (CGM) with insulin pump (continuous subcutaneous insulin infusion [CSII]), known as artificial pancreas, can help optimize glycemic control in diabetes. We present a fundamental modular concept for CLC design,...

  • Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms. Doyle III, Francis J.; Huyett, Lauren M.; Joon Bok Lee; Zisser, Howard C.; Dassau, Eyal // Diabetes Care;May2014, Vol. 37 Issue 5, p1191 

    In this two-part Bench to Clinic narrative, recent advances in both the preclinical and clinical aspects of artificial pancreas (AP) development are described. In the preceding Bench narrative, Kudva and colleagues provide an in-depth understanding of the modified glucoregulatory physiology of...

  • DISCOVERY. Dinsmoor, Rob // Countdown;Summer2008, Vol. 29 Issue 2, Special section p14 

    The article discusses the significance of artificial pancreas. Artificial pancreas is actually an insulin pump that automatically changes its insulin output to meet the body's need from one moment to another. It emphasizes that such pancreas has a glucose monitor which will change the insulin...

  • Cybersecurity risk with Medtronic MiniMed insulin pumps.  // Reactions Weekly;7/13/2019, Vol. 1761 Issue 1, p1 

    No abstract available.

  • Closed-loop artificial pancreas was feasible, effective in adolescents.  // Endocrine Today;8/10/2008, Vol. 6 Issue 14, p18 

    The article discusses research being done on closed-loop artificial pancreas. It references a study published in a 2008 issue of "Diabetes Care." Researchers from Yale University School of Medicine in New Haven, Connecticut examined the feasibility of a closed-loop artificial pancreas the...

  • What is artificial endocrine pancreas? Mechanism and history. Nishida, Kenro; Shimoda, Seiya; Ichinose, Kenshi; Araki, Eiichi; Shichiri, Motoaki; Buechler, Christa // World Journal of Gastroenterology;9/7/2009, Vol. 15 Issue 33, p4105 

    The artificial endocrine pancreas is a feedback control instrument that regulates insulin delivery on a minute-by-minute basis according to measured blood glucose levels. Only one type of bedside-type artificial endocrine pancreas is now available in Japan: STG-22 (Nikkiso Co. Ltd., Japan). In...

  • Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. Weinzimer, Stuart A.; Steil, Garry M.; Swan, Karena L.; Dziura, Jim; Kurtz, Natalie; Tamborlane, William V. // Diabetes Care;May2008, Vol. 31 Issue 5, p934 

    OBJECTIVE -- The most promising β-cell replacement therapy for children with type 1 diabetes is a closed-loop artificial pancreas incorporating continuous glucose sensors and insulin pumps. The Medtronic MiniMed external physiological insulin delivery (ePID) system combines an external pump...

  • Artificial Pancreas Reduces Highs & Hypos. GUINTON, JENNY; GREENWOOD, NIGEL // Australasian Science;Jun2013, Vol. 34 Issue 5, p27 

    The article discusses research about a machine-intelligent artificial pancreas software. The software was tested on simulated diabetic patients. Personalized models of the blood glucose level (BGL) processes were reconstructed. The validity of the personalized models were verified by the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics